Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib vs Adalimumab in RA Feasibility Study
NCT05153200Phase 4Unknown
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Jan 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, single-blind trial of upadacitinib in rheumatoid arthritis (RA) (2 arms), sponsored by Ottawa Hospital Research Institute. Primary endpoints: Recruitment Rate at 1 year and Retention Rate at 6 months. Status: unknown.
02
Drugs
upadacitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05153200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05153200.